文献速递神经肿瘤

内镜经蝶垂体腺瘤术后鞍区血肿再手术的发生率与危险因素

Incidence and risk factors associated with reoperation for sellar hematoma following endoscopic transsphenoidal pituitary surgery.
PubMed 文献 · J Neurosurg · 2019-08-23

该研究基于Weill Cornell Medicine 13年前瞻性数据库,583例内镜经蝶垂体腺瘤手术中9例(1.5%)因鞍区血肿需再手术。P<0.05)是独立预测因素。血肿清除后88%患者视力改善,但78%出现新发内分泌功能障碍。

要点

  • 内镜经蝶术后鞍区血肿再手术率为1.5%,肿瘤≥30 mm者达5%。
  • 肿瘤直径≥30 mm和鞍上扩展是独立危险因素。
  • 血肿清除后88%视力改善,但78%出现新发内分泌功能障碍。

核心结论

  • 内镜经蝶垂体腺瘤术后需再手术的鞍区血肿罕见,多表现为视力下降和头痛。
  • 肿瘤直径≥30 mm和鞍上扩展是最可靠的独立危险因素。
  • 血肿清除可改善视力,但长期内分泌功能障碍常发生。

研究设计与样本

  • 回顾性分析Weill Cornell Medicine 13年前瞻性数据库的内镜经蝶垂体腺瘤手术病例。
  • 583例手术患者中9例因确认血肿需再手术,并与无术后血肿的连续病例对照比较。
  • 采用单因素和多因素二元逻辑回归分析人口学数据和危险因素。

主要发现

  • 583例中9例(1.5%)因鞍区血肿需再手术清除。
  • 9例再手术患者均表现为视力恶化,67%有严重头痛,78%出现新发内分泌功能障碍。
  • 血肿清除后88%患者视力改善,平均清除时间4.5天。
  • 血肿患者中位住院8天(范围4-210天),对照组中位3天(范围1-32天)(P<0.005)。
  • 单因素分析显著危险因素包括肿瘤直径≥30 mm、鞍上扩展、肿瘤体积、海绵窦侵犯、促性腺激素细胞组织学、抗血小板药物使用和BMI升高(均P<0.05)。

关键数值与推荐

  • 肿瘤≥30 mm者血肿发生率为5%(7/139)。

临床怎么用

  • 对肿瘤直径≥30 mm或伴鞍上扩展的高危患者,术后应密切监测。
  • 出现视力恶化或严重头痛时需警惕鞍区血肿,及时评估再手术指征。
  • 血肿清除可改善视力,但需关注长期内分泌功能障碍的发生。

局限性

  • 单中心回顾性设计,血肿再手术事件数少(9例),可能限制统计效能。
  • 对照组为无术后血肿的连续病例,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Postoperative sellar hematoma is an uncommon complication of endonasal endoscopic transsphenoidal surgery (EETS) for pituitary adenoma that often requires emergency surgical evacuation. Sellar hematomas can cause mass effect and compress parasellar structures, leading to clinically significant symptoms such as visual impairment and severe headache. The objective of this study was to determine the incidence and risk factors associated with reoperation for postoperative hematoma after EETS for pituitary adenoma. METHODS: The authors reviewed a prospectively acquired database of EETS for pituitary adenoma over 13 years at Weill Cornell Medicine, NewYork-Presbyterian Hospital and identified cases that required reoperation for confirmed hematoma. They also reviewed clinical and radiographic data of a consecutive series of patients undergoing EETS for pituitary adenoma who did not have postoperative hematoma, which served as the control group. Demographic data and risk factors were compared between the groups using univariate and multivariate analyses via binary logistic regression. RESULTS: Among a cohort of 583 patients undergoing EETS for pituitary adenoma, 9 patients (1.5%) required operation for sellar hematoma evacuation. All 9 patients with reoperation for sellar hematoma presented with worsening in their vision, and severe headache was present in 67%. New postoperative endocrine dysfunction developed in 78%. Clot evacuation improved vision in 88%. The mean time to hematoma evacuation was 4.5 days. The median length of stay for patients with sellar hematoma was 8 days (range 4-210 days) compared with a median length of stay of 3 days (range 1-32 days) for the control patients (p < 0.005). Significant risk factors in univariate analysis were tumor diameter ≥ 30 mm (p < 0.005), suprasellar extension (p < 0.005), tumor volume (p < 0.005), cavernous sinus invasion (p < 0.05), gonadotroph histology (p < 0.05), antiplatelet use (p < 0.05), and elevated BMI (p < 0.05). On multivariate analysis, tumor diameter ≥ 30 mm (OR 4.555, CI 1.30-28.90; p < 0.05) and suprasellar extension (OR 1.048, CI 1.01-1.10; p < 0.05) were found to be the only independent predictors of sellar hematoma. The incidence of hematoma in tumors ≥ 30 mm was 5% (7/139). CONCLUSIONS: Postoperative sellar hematoma requiring reoperation is a rare phenomenon after transsphenoidal surgery, often presenting with visual loss and headache. Clot evacuation results in improvement in vision, but long-term endocrinopathy often ensues. Tumor diameter ≥ 30 mm and suprasellar extent are the most reliable risk factors. Close postoperative scrutiny should be given to patients at high risk.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Younus I, Gerges MM, Godil SS, et al. Incidence and risk factors associated with reoperation for sellar hematoma following endoscopic transsphenoidal pituitary surgery. J Neurosurg. 2019. PMID: 31443077. doi:10.3171/2019.6.JNS191169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。